Recent Updates
Recently added Catalysts
TIL Positive Sentiment

Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Thursday, August 13, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Instil Bio, a biotechnology company, has announced its financial results for the second quarter of 2026. The report highlights the company's ongoing commitment to developing innovative therapeutics. This update reflects Instil's progress and future direction in the biopharmaceutical sector.

Market Sentiment Analysis

POSITIVE FACTORS

  • Instil Bio reported its financial results for Q2 2026.
  • The company is focused on advancing innovative therapeutics.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~165 mo
Minimal dilution risk
Lead asset
AXN-2510
Phase 1 · Solid Tumor, Adult

Full Press Release Details

DALLAS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its second quarter 2026 financial results and provided a corporate update.

Frequently Asked Questions

What financial results did Instil Bio report?

Instil Bio reported its financial results for the second quarter of 2026.

What is Instil Bio focused on?

Instil Bio focuses on identifying and advancing innovative therapeutics.

ShareAdd on Google
Tags: TIL Viatris Investor Conferences Healthcare Instil Bio financial results biotechnology therapeutics
Last updated: Aug 13, 2026

Biotech snapshot

Cash runway
$75M liquidity · $0M/mo burn
~165 mo
Minimal dilution risk
Lead asset
AXN-2510Phase 1
Solid Tumor, Adult →